EP0666923A4 - Apport cible de polynucleotides ou d'oligonucleotides a des cellules. - Google Patents

Apport cible de polynucleotides ou d'oligonucleotides a des cellules.

Info

Publication number
EP0666923A4
EP0666923A4 EP19920920863 EP92920863A EP0666923A4 EP 0666923 A4 EP0666923 A4 EP 0666923A4 EP 19920920863 EP19920920863 EP 19920920863 EP 92920863 A EP92920863 A EP 92920863A EP 0666923 A4 EP0666923 A4 EP 0666923A4
Authority
EP
European Patent Office
Prior art keywords
oligonucleotides
poly
cells
targeted delivery
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19920920863
Other languages
German (de)
English (en)
Other versions
EP0666923A1 (fr
Inventor
George Y Wu
Catherine H Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Publication of EP0666923A4 publication Critical patent/EP0666923A4/fr
Publication of EP0666923A1 publication Critical patent/EP0666923A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
EP92920863A 1991-09-05 1992-09-04 Apport cible de polynucleotides ou d'oligonucleotides a des cellules Ceased EP0666923A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75508391A 1991-09-05 1991-09-05
US755083 1991-09-05
US78811991A 1991-11-04 1991-11-04
US788119 1991-11-04
US86400392A 1992-04-03 1992-04-03
US864003 1992-04-03
PCT/US1992/007339 WO1993004701A1 (fr) 1991-09-05 1992-09-04 Apport cible de polynucleotides ou d'oligonucleotides a des cellules

Publications (2)

Publication Number Publication Date
EP0666923A4 true EP0666923A4 (fr) 1995-01-20
EP0666923A1 EP0666923A1 (fr) 1995-08-16

Family

ID=27419474

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92920863A Ceased EP0666923A1 (fr) 1991-09-05 1992-09-04 Apport cible de polynucleotides ou d'oligonucleotides a des cellules

Country Status (6)

Country Link
EP (1) EP0666923A1 (fr)
JP (1) JPH07500820A (fr)
KR (1) KR100252547B1 (fr)
AU (1) AU681997B2 (fr)
CA (1) CA2116107A1 (fr)
WO (1) WO1993004701A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US7550561B1 (en) 1991-05-16 2009-06-23 Cold Spring Harbor Laboratory p16INK4 polypeptides
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
JPH08503366A (ja) * 1992-11-09 1996-04-16 トーマス・ジェファーソン・ユニバーシティ コラーゲンの突然変異および野生型遺伝子の発現を阻害するアンチセンスオリゴヌクレオチド
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US6043030A (en) * 1992-12-17 2000-03-28 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6331390B1 (en) 1992-12-17 2001-12-18 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
EP0681482B1 (fr) * 1993-01-22 2005-12-07 University Research Corporation Localisation d'agents therapeutiques
WO1994023050A1 (fr) * 1993-04-05 1994-10-13 University Of Connecticut Apport cible de genes codant des polyribonucleotides antisens
WO1994023751A1 (fr) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Peptides de tranfert d'acides nucleiques et leur utilisation pour injecter des acides nucleiques dans des cellules eucaryotes
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
DE4331011A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
DE4331012A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US7691632B2 (en) 1993-11-18 2010-04-06 Cold Spring Harbor Laboratory Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
WO1995022618A1 (fr) * 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Systeme de liberation d'acide nucleique, son procede de synthese et ses utilisations
EP0759087B1 (fr) * 1994-05-13 2001-03-28 Chiron Corporation Compositions et procedes de criblage de vecteurs d'apport de genes
FR2721612B1 (fr) * 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
DE4427980A1 (de) * 1994-08-08 1996-02-15 Bayer Ag Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
WO1996024378A2 (fr) 1995-02-10 1996-08-15 Worcester Foundation For Biomedical Research, Inc. Apport de composes exogenes
AU5122796A (en) * 1995-03-31 1996-10-16 Drug Delivery System Institute, Ltd. Amidite derivatives and oligonucleotide derivatives
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
DK0973928T3 (da) 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
CN1263473A (zh) 1997-05-21 2000-08-16 利兰·斯坦福青年大学托管委员会 增加跨生物膜转运的组合物和方法
WO1998055611A1 (fr) * 1997-06-06 1998-12-10 Regents Of The University Of Michigan Element de reponse a la neureguline et ses utilisations
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
AU9678598A (en) 1997-10-01 1999-04-23 Dana-Farber Cancer Institute Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain
AU742241B2 (en) * 1998-02-11 2001-12-20 Applera Corporation PNA and DNA conjugates and methods for preparation thereof
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
DE19858005B4 (de) * 1998-12-16 2007-02-08 november Aktiengesellschaft, Gesellschaft für Molekulare Medizin Synthetisches Nucleinsäure-Partikel
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2001013957A2 (fr) 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
ATE492644T1 (de) * 1999-09-09 2011-01-15 Curevac Gmbh Transfer von mrna unter verwendung von polykationischen verbindungen
WO2001072765A1 (fr) * 2000-03-28 2001-10-04 Isis Pharmaceuticals, Inc. Modification de comportement cellulaire par modulation antisens de la maturation d'arn messager
EP1286699A2 (fr) * 2000-05-19 2003-03-05 Regents Of The University Of Minnesota Composition pour l'introduction de composes dans des cellules
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
WO2002079447A2 (fr) 2001-03-30 2002-10-10 Avigenics, Inc. Promoteur de lysozymes aviaires
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
AU2003231048A1 (en) 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
ES2387985T3 (es) 2002-11-26 2012-10-05 Abbott Biotherapeutics Corp. Anticuerpos quiméricos y humanizados de integrina alfa 5 beta 1 que modulan la angiogénesis
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
WO2005058937A2 (fr) 2003-12-12 2005-06-30 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epitope de lymphocyte t cytotoxique humain et son epitope agoniste issus du nombre non variable de sequences repetees en tandem de muc-1
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
EP1848698B1 (fr) 2005-01-25 2013-03-13 Prolexys Pharmaceuticals, Inc. Dérivés de quinoxaline en tant qu'agents contre des tumeurs
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
EP2111553B1 (fr) 2007-01-24 2018-09-19 Carnegie Mellon University Biocapteurs optiques
EP2222701B1 (fr) 2007-12-06 2017-11-01 Dana-Farber Cancer Institute, Inc. Anticorps contre le virus de la grippe et procédés pour leur utilisation
CA2752854A1 (fr) 2009-02-18 2010-08-26 Carnegie Mellon University Colorants dendrimeres desactives pour detection de brillant
KR101811886B1 (ko) 2009-05-05 2017-12-22 노비뮨 에스 에이 항―ｉｌ―17ｆ 항체 및 이의 사용 방법
EP4089169A1 (fr) 2009-10-12 2022-11-16 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
CN108404123A (zh) 2010-01-15 2018-08-17 康奈尔大学 降低细胞内蛋白质水平的方法
JP2013517772A (ja) 2010-01-21 2013-05-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 遺伝子発見および標的確認を補助するための状況特異的遺伝子スクリーニングプラットフォーム
EP2577309B1 (fr) 2010-05-25 2016-11-23 Carnegie Mellon University Sondes ciblées de physiologie cellulaire
CA2800531C (fr) 2010-06-02 2021-05-25 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humanises et methodes d'utilisation
EP2659271A4 (fr) 2010-12-27 2015-04-08 Univ Brown Méthodes thérapeutiques et diagnostiques impliquant le biglycane et l'utrophine
PL2831117T3 (pl) 2012-03-29 2018-03-30 Novimmune Sa Przeciwciała anty-TLR4 i ich zastosowania
EP2844674A1 (fr) 2012-05-04 2015-03-11 Dana-Farber Cancer Institute, Inc. Anticorps anti-ccr4 monoclonaux humanisés maturés par affinité et leurs procédés d'utilisation
CA3139031A1 (fr) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
CN105121467B (zh) 2012-12-03 2019-07-05 诺夫免疫股份有限公司 抗cd47抗体及其使用方法
CA2940196C (fr) 2014-03-19 2023-03-07 Wayne Marasco Restriction immunogenetique sur l'elicitation des anticorps
EP4112070A1 (fr) 2014-04-25 2023-01-04 Dana Farber Cancer Institute, Inc. Anticorps neutralisant le coronavirus du syndrome respiratoire du moyen-orient et leurs procédés d'utilisation
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
MX2017004311A (es) 2014-10-03 2017-12-07 Dana Farber Cancer Inst Inc Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
US10675349B2 (en) 2014-10-06 2020-06-09 Dana-Farber Cancer Institute, Inc. Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
CN107429075B (zh) 2014-11-17 2022-11-01 卡内基梅隆大学 可激活的双组份光敏剂
CN107406503B (zh) 2014-11-18 2021-07-16 詹森药业有限公司 Cd47抗体、方法和用途
WO2017136676A1 (fr) 2016-02-05 2017-08-10 Nanoview Diagnostics Inc. Détection d'exosomes ayant des marqueurs de surface
KR102413037B1 (ko) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
SG11201900500TA (en) 2016-07-22 2019-02-27 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
US10870694B2 (en) 2016-09-02 2020-12-22 Dana Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
EP3509633A1 (fr) 2016-09-06 2019-07-17 Dana-Farber Cancer Institute, Inc. Procédés de traitement ou de prévention d'une infection par le virus zika
WO2018049261A1 (fr) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Virus oncolytique exprimant des modulateurs du point de contrôle immunitaire
AU2019235523A1 (en) 2018-03-14 2020-10-29 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROTHENBERG, M. ET AL.: "Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 81, no. 20, 18 October 1989 (1989-10-18), BETHESDA, MD, USA, pages 39 - 44, XP000351436 *
See also references of WO9304701A1 *
WU, G. & WU, C.: "DELIVERY SYSTEMS FOR GENE THERAPY.", BIOTHERAPY (DORDR) 3 (1). 1991. 87-96 *
WU, G. ET AL.: "RECEPTOR-MEDIATED IN-VITRO GENE TRANSFORMATION BY A SOLUBLE DNA CARRIER SYSTEM.", J BIOL CHEM 262 (10). 1987. 4429-4432 *

Also Published As

Publication number Publication date
AU681997B2 (en) 1997-09-18
CA2116107A1 (fr) 1993-03-18
JPH07500820A (ja) 1995-01-26
WO1993004701A1 (fr) 1993-03-18
KR100252547B1 (ko) 2000-09-01
AU2678092A (en) 1993-04-05
EP0666923A1 (fr) 1995-08-16

Similar Documents

Publication Publication Date Title
EP0666923A4 (fr) Apport cible de polynucleotides ou d'oligonucleotides a des cellules.
NO943198D0 (no) Antisensoligonukleotidinhibering av papillomavirus
EP0654973A4 (fr) Systeme d'administration d'un medicament aux tissus lyphatiques.
GB2209280B (en) Dosage form comprising fast agent delivery followed by slow agent delivery
GB9723081D0 (en) Dosage form comprising oxybutynin
IL105824A0 (en) Single use intrauterine injector
EP0690716A4 (fr) OLIGONUCLEOTIDES MODIFIES POUR AMELIORER LA STABILITE A pH ACIDE
GB9224640D0 (en) Stable oligonucleotides
GB9225427D0 (en) Oligonucleotides with rna cleavage activity
ZA958381B (en) Regulated genes by stimulation of chondrocytes with 1l-1beta
EP0667778A4 (fr) Traitement d'un melanome au moyen d'oligonucleotides anti-codants par rapport au proto-oncogene c-myb.
ITMI921235A1 (it) Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
PH31659A (en) Therapeutic nucleotides.
EP0489846A4 (en) Antisense oligonucleotides to c-abl proto-oncogene
GB2266740B (en) Arch structure
IL99172A0 (en) Antisense oligonucleotides which are active as antiviral agents
AU1562492A (en) Substituted salicylamides, agents to combat plant diseases
DE3369680D1 (en) Benzotriazoles, their preparation and use as biocides
AU5086393A (en) Antisense oligonucleotides to cyclin d1 proto-oncogene
AU5136693A (en) Antisense oligonucleotides to b myb proto-oncogene
EP0580795A4 (en) Antisense oligonucleotides to c-kit proto-oncogene and uses thereof
ITMI941560A0 (it) Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
ZA928126B (en) Use of substituted tetrahydrothiophenes, some of wich are known as medicaments, new active substances and processes for their preparation.
DE69320154D1 (de) Menschliche Id-Gene
Cribb Path to glory: the social impact of the growth of mormonism.

Legal Events

Date Code Title Description
A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19970513

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20030306